SCHEMBL21623534

SCHEMBL21623534

Nc1ccc(S(N)(=O)=O)cc1C(=O)Nc1cc(F)c(F)c(F)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.58
▸ CA1 P00915 14/20 0.56
▸ CA2 P00918 14/20 0.56
▸ CA9 Q16790 9/20 0.56
▸ CA12 O43570 1/20 0.50
▸ CA4 P22748 1/20 0.50
▸ CA6 P23280 1/20 0.50
▸ CA5A P35218 1/20 0.50
▸ CA7 P43166 1/20 0.50
▸ CA14 Q9ULX7 1/20 0.50
▸ CA5B Q9Y2D0 1/20 0.50
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ KCNH2 Q12809 1/20 0.47
▸ KMT2A Q03164 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21626517 0.79 MAPT (0.69) MAPTLMNAPOLB
SCHEMBL21623556 0.78 TP53 (0.56) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL21623554 0.78 TP53 (0.56) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL21623553 0.78 CYP3A4 (0.73) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL15847661 0.78 MAPT (0.61) CA1CA2CA9CA12MAPT
SCHEMBL21623376 0.76 CYP1A2 (0.65) CYP1A2CA1CA2CA9CA12
SCHEMBL15076500 0.75 MAPT (0.52) CYP1A2CA1CA2CA9KMT2A
Hydrochloric Acid SCHEMBL28824808 0.75 TP53 (0.53) CYP1A2CA1CA2CA9KMT2A
SCHEMBL21623165 0.75 CYP1A2 (0.75) CYP1A2CA1CA2CA9CA12
SCHEMBL21623334 0.74 CYP1A2 (1.00) CYP1A2CA1CA2CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210276967-A1 INHIBITORS OF HEPATITIS B VIRUS OSPEDALE SAN RAFFAELE S.R.L. (IT) 2021-09-09 — — US disclosed
US-20210276967-A1 INHIBITORS OF HEPATITIS B VIRUS OSPEDALE SAN RAFFAELE S.R.L. (IT) 2021-09-09 — — US disclosed
WO-2020016427-A1 INHIBITORS OF HEPATITIS B VIRUS OSPEDALE SAN RAFFAELE S.R.L. (IT) 2020-01-23 — — WO disclosed
EP-3597637-A1 INHIBITORS OF HEPATITIS B VIRUS IRBM S.P.A. (IT) 2020-01-22 — — EP disclosed
EP-3597637-A1 INHIBITORS OF HEPATITIS B VIRUS IRBM S.P.A. (IT) 2020-01-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210276967-A1 INHIBITORS OF HEPATITIS B VIRUS HAVCR2, SLC10A1, HDGF CYP1A2 1300/4885CA1 3251/4885CA2 3007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback